Objective:To study of the serum sFas and sICAM-1 correlate with the disease activity and the value of therapeutic prediction in systemic lupus erythematosus(SLE). Methods:Serum sFas and sICAM-1 levels in patients with SLE and healthy controls were detected by using a commercially available ELISA system, and the correlation of the levels of sFas and sICAM-1 in SLE patients were analyzed with SLEDAI scores and other immune markers(ANA,ds-DNA etc). The judgment of disease activity with the levels of sFas and sICAM-1 was also studied. Results:The average levels of sFas and sICAM-1 in SLE patients were respectively 4.18 -滋g/L and 464.5 -滋g/L,higher than that in the healthy controls. The sFas and sICAM-1 in the healthy controls were 2.27 -滋g/L and 190.4 -滋g/L. Serum levels of sFas and sICAM-1 were significantly higher in active SLE patients than in inactive patients(P < 0.001). Serum levels of sFas and sICAM-1 were significantly higher in patients with higher concentration of ANA,positive ds-DNA antibody and damaged of renal function than that with lower concentration of ANA,negative ds-DNA antibody and normal of renal function. The serological levels of sFas and sICAM-1 were shown to have a positive correlation with SLEDAI scores(r = 0.688 and r = 0.728). The average levels ± SD of sFas and sICAM-1 in inactive SLE patients were used as the critical value. The quatitative detection of serum sFas( > 4.45 -滋g/L) and sICAM-1(438.6 -滋g/L) had higher sensitivity and specificity to the value of therapeutic prediction. Conclusion:The results suggested that sFas and sICAM-1 should play certain roles in the pathogenesis of SLE,and might be correlated with the disease activity. The quatitative detection of serum sFas and sICAM-1 should be the helpful for therapeutic prediction in systemic lupus erythematosus.